BioAffinity Technologies (BIAF) announced it has received a notification of allowance from the United States Patent and Trademark Office for a new patent covering the AI-built algorithm and flow cytometry platform that analyzes cell populations in sputum leading to detection of lung cancer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Regains Nasdaq Compliance, Ensures Continued Trading
- BioAffinity Technologies regains compliance with Nasdaq
- bioAffinity Technologies Announces $1.8M Direct Offering
- BioAffinity Technologies announces closing of $1.8M registered direct offering
- BioAffinity Technologies announces $1.8M registered direct offering